Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 829401108 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
RA Capital Management, L.P.
13D/A
Amendment 2
|
14.3% |
9/21/2026
Event 9/17/2026
|
|
| RA Capital Management, L.P. | 14.3% | ||
| Peter Kolchinsky | 14.3% | ||
| Rajeev Shah | 14.3% | ||
| RA Capital Healthcare Fund, L.P. | 7.6% | ||
| RA Capital Nexus Fund III, L.P. | 4.9% | ||
|
Viking Global Investors LP
13G/A
Amendment 1
|
7.1% |
5/15/2026
Event 3/31/2026
|
|
| Viking Global Investors LP | 7.1% | ||
| Viking Global Opportunities Parent GP LLC | 7.1% | ||
| Viking Global Opportunities GP LLC | 4.5% | ||
| Viking Global Opportunities Portfolio GP LLC | 4.5% | ||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 4.5% | ||
| Viking Global Opportunities Drawdown GP LLC | 2.6% | ||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 2.6% | ||
| Viking Global Opportunities Drawdown (Aggregator) LP | 2.6% | ||
| Halvorsen Ole Andreas | 7.1% | ||
| Shabet Rose Sharon | 7.1% | ||
|
Qatar Investment Authority
13G/A
Amendment 1
|
4.5% |
5/12/2026
Event 3/31/2026
|
|
| Qatar Investment Authority | 4.5% | ||
| Q Healthcare Holding LLC | 4.5% | ||
|
Orbimed Advisors LLC
13D/A
Amendment 1
|
6.6% |
4/20/2026
Event 4/15/2026
|
|
| Orbimed Advisors LLC | 6.6% | ||
| OrbiMed Capital GP VIII LLC | 6.6% | ||
|
RA Capital Management, L.P.
13D/A
Amendment 1
|
22.6% |
11/7/2025
Event 11/5/2025
|
|
| RA Capital Management, L.P. | 22.6% | ||
| Peter Kolchinsky | 22.6% | ||
| Rajeev Shah | 22.6% | ||
| RA Capital Healthcare Fund, L.P. | 15.5% | ||
| RA Capital Nexus Fund III, L.P. | 5.0% | ||
| JPMorgan Chase & Co 13G/A Amendment 1 | 4.4% |
10/31/2025
Event 9/30/2025
|
|
|
Atlas Venture Fund XI, L.P.
13D/A
Amendment 1
|
5.4% |
10/20/2025
Event 10/16/2025
|
|
| Atlas Venture Fund XI, L.P. | 5.4% | ||
| Atlas Venture Associates XI, L.P. | 5.4% | ||
| Atlas Venture Associates XI, LLC | 5.4% | ||
| Atlas Venture Opportunity Fund II, L.P. | 1.6% | ||
| Atlas Venture Associates Opportunity II, LP | 1.6% | ||
| Atlas Venture Associates Opportunity II, LLC | 1.6% | ||
| JPMorgan Chase & Co 13G | 5.0% |
7/30/2025
Event 6/30/2025
|
|
|
Qatar Investment Authority
13G
|
5.0% |
6/16/2025
Event 6/11/2025
|
|
| Qatar Investment Authority | 5.0% | ||
| Q Healthcare Holding LLC | 5.0% | ||
|
TPG GP A, LLC
13D
|
15.2% |
2/18/2025
Event 2/10/2025
|
|
| TPG GP A, LLC | 15.2% | ||
| James G. Coulter | 15.2% | ||
| Jon Winkelried | 15.2% | ||
|
Atlas Venture Fund XI, L.P.
13D
|
6.5% |
2/18/2025
Event 2/10/2025
|
|
| Atlas Venture Fund XI, L.P. | 6.5% | ||
| Atlas Venture Associates XI, L.P. | 6.5% | ||
| Atlas Venture Associates XI, LLC | 6.5% | ||
| Atlas Venture Opportunity Fund II, L.P. | 1.8% | ||
| Atlas Venture Associates Opportunity II, LP | 1.8% | ||
| Atlas Venture Associates Opportunity II, LLC | 1.8% | ||
|
RA Capital Management, L.P.
13D
|
23.7% |
2/18/2025
Event 2/10/2025
|
|
| RA Capital Management, L.P. | 23.7% | ||
| Peter Kolchinsky | 23.7% | ||
| Rajeev Shah | 23.7% | ||
| RA Capital Healthcare Fund, L.P. | 15.7% | ||
| RA Capital Nexus Fund III, L.P. | 5.3% | ||
|
Enavate Sciences GP, LLC
13D
|
5.6% |
2/18/2025
Event 2/10/2025
|
|
| Enavate Sciences GP, LLC | 5.6% | ||
| Sionna Aggregator, LP | 5.6% | ||
|
Viking Global Investors LP
13G
|
6.7% |
2/14/2025
Event 2/10/2025
|
|
| Viking Global Investors LP | 6.7% | ||
| Viking Global Opportunities Parent GP LLC | 6.7% | ||
| Viking Global Opportunities GP LLC | 4.3% | ||
| Viking Global Opportunities Portfolio GP LLC | 4.3% | ||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 4.3% | ||
| Viking Global Opportunities Drawdown GP LLC | 2.4% | ||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 2.4% | ||
| Viking Global Opportunities Drawdown (Aggregator) LP | 2.4% | ||
| Halvorsen Ole Andreas | 6.7% | ||
| Ott David C. | 6.7% | ||
| Shabet Rose Sharon | 6.7% | ||
|
Orbimed Advisors LLC
13D
|
8.4% |
2/13/2025
Event 2/10/2025
|
|
| Orbimed Advisors LLC | 8.4% | ||
| OrbiMed Capital GP VIII LLC | 8.4% |